Edition:
India

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,784.50GBp
21 Feb 2018
Change (% chg)

62.50 (+1.32%)
Prev Close
4,722.00
Open
4,717.00
Day's High
4,786.00
Day's Low
4,699.00
Volume
1,025,034
Avg. Vol
2,286,177
52-wk High
5,585.07
52-wk Low
4,260.00

Select another date:

Tue, Feb 20 2018

BRIEF-Ionis Licences New Antisense Drug For Kidney Disease To Astrazeneca

* IONIS LICENCES NEW ANTISENSE DRUG FOR KIDNEY DISEASE TO ASTRAZENECA

AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

AstraZeneca's immunotherapy drug wins key lung cancer approval

LONDON AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.

BRIEF-AstraZeneca ‍Says US FDA Approves Imfinzi For Unresectable Stage III Non-Small Cell Lung Cancer​

* ‍US FDA APPROVES IMFINZI FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER​

UPDATE 1-AstraZeneca's immunotherapy drug wins key lung cancer approval

* Rival BMS, Merck, Roche drugs approved for later disease (Adds details on competition, size of market opportunity)

U.S. FDA approves AstraZeneca's immunotherapy for lung cancer

Feb 16 The U.S. Food and Drug Administration on Friday granted approval for expanded use of AstraZeneca Plc's , immunotherapy drug, Imfinzi, to treat non-small cell lung cancer whose tumors can't be surgically removed.

BRIEF-U.S. FDA Expands Approval Of Imfinzi To Reduce The Risk Of Non-Small Cell Lung Cancer Progressing

* U.S. FDA EXPANDS APPROVAL OF IMFINZI TO REDUCE THE RISK OF NON-SMALL CELL LUNG CANCER PROGRESSING

BRIEF-Astrazeneca Says ‍Selumetinib In Nf1 Gets FDA Orphan Drug Status​

* US FDA GRANTED ORPHAN DRUG DESIGNATION (ODD) FOR SELUMETINIB, A MEK 1/2 INHIBITOR, FOR TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1)​

BRIEF-AstraZeneca Says Prolonging Treatment With Brilinta After 1-Yr Reduces Risk Of Major Adverse Cardiac Events By 19 Pct

* ‍BRILINTA SIGNIFICANTLY REDUCES CV EVENTS AND CORONARY DEATH BEYOND ONE YEAR IN HEART ATTACK SURVIVORS WITH MULTI-VESSEL DISEASE​ Further company coverage:

AstraZeneca flags return to drug growth in 2018, China shines

LONDON AstraZeneca expects a return to drug sales growth in 2018 as new medicines win market share and the group puts patent losses behind it, although the need to invest in launches will weigh on profit this year.

Select another date: